Efficacy News and Research

RSS

Experimental treatment for multiple sclerosis reverses disorder in mice

A new experimental treatment for multiple sclerosis (MS) completely reverses the devastating autoimmune disorder in mice, and might work exactly the same way in humans, say researchers at the Jewish General Hospital Lady Davis Institute for Medical Research and McGill University in Montreal.

11 Aug 2009

Upstream Biosciences actively seeking licensors or acquirers for anti-parasitic drug discovery portfolio and cancer diagnostic platform

Upstream Biosciences Inc. (OTCBB: UPBS) has announced that the company is actively seeking licensors or acquirers for its novel anti-parasitic drug discovery portfolio and cancer diagnostic platform.

11 Aug 2009

Holography helps tackle ovarian cancer

Two University of Arizona researchers have formed a research team to design, build and evaluate two versions of an ovarian cancer medical imaging and screening instrument that will use holographic components in a new type of optical microscope.

11 Aug 2009

Depomed reports promising results in phase I trial for DM-1992 in Parkinson’s

Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson’s patients, DM-1992, Depomed’s investigative novel gastric retentive extended-release formulation of levodopa/carbidopa, extended coverage above levodopa’s efficacious threshold and extended the time to peak levodopa concentration relative to currently available sustained release levodopa/carbidopa formulations.

11 Aug 2009

Additional trial to be conducted for KYNAPID under FDA special protocol agreement

Cardiome Pharma Corp. (NASDAQ: CRME/TSX: COM) and its co-development partner Astellas Pharma US, Inc. ("Astellas") announced today that Astellas will undertake a single confirmatory additional Phase 3 clinical trial of KYNAPID(TM) (vernakalant hydrochloride) Injection for rapid conversion of atrial fibrillation to sinus rhythm. The trial, to be called ACT 5, is expected to begin enrolling patients by the end of 2009, with completion expected in the first half of 2011.

11 Aug 2009

Eiger Biopharmaceuticals starts CLEAN-1 HCV phase 1B trial

Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today that the first patients have been dosed in an innovative clinical trial in patients chronically infected with the hepatitis C virus (HCV). The trial, run in centers in Australia and New Zealand, will investigate the antiviral effect of clemizole monotherapy in the absence of interferon.

10 Aug 2009

Electrodiagnostic and neuromuscular medicine featured at AANEM annual meeting

The American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) will hold its 56th annual meeting in San Diego, California, from October 7-10, 2009 at the Manchester Grand Hyatt.

10 Aug 2009

Array Biopharma reports Q4 and full year 2009 financials

Array reported revenue of $5.5 million for the fourth quarter of fiscal 2009, compared to revenue of $6.1 million for the same period in fiscal 2008. Array invested $21.3 million in proprietary research and development for the quarter to advance its seven wholly-owned drugs in clinical development and select discovery programs.

10 Aug 2009

Gtx, Inc. reports Q2 2009 results

GTx, Inc. (Nasdaq: GTXI) today reported financial results for the second quarter of 2009. The net loss for the second quarter and six months ended June 30, 2009 was $11.3 million and $22.6 million, respectively, compared with a net loss of $13.2 million and $26.0 million for the same periods in 2008. At June 30, 2009 GTx had cash, cash equivalents and short-term investments of $68.9 million.

10 Aug 2009

Chemists rationally design inhibitors against an RNA molecule that causes myotonic muscular dystrophy

Chemists at the University at Buffalo have used rational drug design to synthesize small, cell-permeable molecules that are effective in vitro against two common types of myotonic muscular dystrophy, a result that has implications for potentially curing muscular dystrophy, as well as other diseases.

9 Aug 2009

Understanding emotional reactions for negative services

Service quality beliefs are usually positively related to customer satisfaction - the higher the perceived service quality, the higher the customer's satisfaction. However, an article published in the August issue of the Journal of Service Research finds this relationship may be more complicated in "negative service environments" (i.e., services that consumers would prefer not to have to use), such as health screening, diagnostic tests, or even auto repair.

9 Aug 2009

Botanicals do not have an effect on hot flashes or on cognitive function in menopausal women

Two studies conducted by researchers at the University of Illinois at Chicago and Northwestern University have found that commonly used botanicals do not have an effect on hot flashes or on cognitive function in menopausal women.

6 Aug 2009

Bellicum Pharmaceuticals starts phase I/II trial of novel advanced prostate cancer vaccine

Bellicum Pharmaceuticals, Inc. today announced dosing of the first patient in a Phase I/II clinical trial of BP-GMAX-CD1, a novel pharmacologically regulated dendritic cell vaccine for the treatment of prostate cancer. The disease-specific trial is being conducted under a Bellicum Investigational New Drug application allowed by the FDA in 2008. The company anticipates reporting initial results of the study in 2010.

6 Aug 2009

Experts on vertebroplasty contend recent vertebroplasty studies are misleading

Two studies released today in the New England Journal of Medicine claim to demonstrate that vertebroplasty, a procedure to treat some painful spine fractures, is not effective. This is incorrect, as both studies actually demonstrate a significant improvement in patients' pain and ability to function normally.

6 Aug 2009

Fast-tracked H1N1 vaccines will not compromise safety, WHO says

Efforts to fast-track the approval of H1N1 (swine) flu vaccines will not compromise the safety or quality controls of vaccine production, the WHO said in a written statement Thursday, the Mail & Guardian reports.

6 Aug 2009

Phytomedical partners with LATITUDE Pharmaceuticals on lead anti cancer compound for glioblastoma

PhytoMedical Technologies, Inc. has announced their partnership with LATITUDE Pharmaceuticals, Inc. to develop an IV Formulation for its lead anti cancer compound for glioblastoma. LATITUDE Pharmaceuticals, Inc. is a widely recognized expert in the area of drug formulations and delivery systems.

6 Aug 2009

Aradigm receives orphan drug designation for inhaled liposomal ciprofloxacin to treat cystic fibrosis in Europe

Aradigm Corporation (OTCBB:ARDM) has announced that the European Medicines Agency (EMEA) granted Orphan Drug Designation to the Company’s inhaled liposomal ciprofloxacin drug product candidate for the treatment of lung infections associated with cystic fibrosis (“CF”).

6 Aug 2009

Khmer Rouge trials - will they heal or exacerbate affects of trauma

As leaders of the former Khmer Rouge regime testify in a human rights tribunal, in harrowing detail, for the killing of more than a million Cambodians from 1975 to 1979 a central medical question remains unanswered: will the trials help a society heal or exacerbate the lingering affects of widespread trauma?

5 Aug 2009

$Questions raised about vertebroplasty for osteoporotic spinal compression fractures$

Questions raised about vertebroplasty for osteoporotic spinal compression fractures

A new study led by Mayo Clinic researchers has found that relief of pain from vertebral compression fractures, as well as improvement in pain-related dysfunction, were similar in patients treated with vertebroplasty and those treated with simulated vertebroplasty without cement injections. The article, “A Randomized Controlled Trial of Vertebroplasty for Osteoporotic Spine Fractures,” was released today in the New England Journal of Medicine.

5 Aug 2009

Plague in China; U.S. contribution to clean water initiatives; TB vaccine trial; HIV in Mozambique; New HIV strain

A third person died of pneumonic plague in China on Monday, local health authorities said, Xinhua reports. The outbreak began on July 30 and an additional nine people in the town of Ziketan are reportedly ill (8/3). "Pneumonic plague, which attacks the lungs, is closely related to bubonic plague," writes the New York Times.

4 Aug 2009

Efficacy News and Research

Experimental treatment for multiple sclerosis reverses disorder in mice

Upstream Biosciences actively seeking licensors or acquirers for anti-parasitic drug discovery portfolio and cancer diagnostic platform

Holography helps tackle ovarian cancer

Depomed reports promising results in phase I trial for DM-1992 in Parkinson’s

Additional trial to be conducted for KYNAPID under FDA special protocol agreement

Eiger Biopharmaceuticals starts CLEAN-1 HCV phase 1B trial

Electrodiagnostic and neuromuscular medicine featured at AANEM annual meeting

Array Biopharma reports Q4 and full year 2009 financials

Gtx, Inc. reports Q2 2009 results

Chemists rationally design inhibitors against an RNA molecule that causes myotonic muscular dystrophy

Understanding emotional reactions for negative services

Botanicals do not have an effect on hot flashes or on cognitive function in menopausal women

Bellicum Pharmaceuticals starts phase I/II trial of novel advanced prostate cancer vaccine

Experts on vertebroplasty contend recent vertebroplasty studies are misleading

Fast-tracked H1N1 vaccines will not compromise safety, WHO says

Phytomedical partners with LATITUDE Pharmaceuticals on lead anti cancer compound for glioblastoma

Aradigm receives orphan drug designation for inhaled liposomal ciprofloxacin to treat cystic fibrosis in Europe

Khmer Rouge trials - will they heal or exacerbate affects of trauma

Questions raised about vertebroplasty for osteoporotic spinal compression fractures

Plague in China; U.S. contribution to clean water initiatives; TB vaccine trial; HIV in Mozambique; New HIV strain

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News